Latest content
-
ReadNanoTemper Technologies welcomes Andreas Schmitz as its first Chief Human Resources Officer
MUNICH, Germany, 18 May 2022 — NanoTemper Technologies, well-known for creating biophysical tools that tackle challenging characterizations, welcomes Andreas Schmitz as the first Chief Human...
-
[New] Dianthus with Spectral Shift
Learn how
Overcome your biggest challenges when characterizing PROTAC binary and ternary complexes. -
ReadLearn more about your protein expression conditions in less time with Andromeda
Learn more about your protein expression conditions in less time with Andromeda
-
Read8 Gene Therapy conferences you should attend in 2022
With the first AAV-based gene therapies approved, and new gene editing strategies emerging, it’s important to stay on top of the latest topics in this therapeutic area. Here are 8 gene therapy...
-
Read9 Targeted Protein Degradation conferences you don’t want to miss in 2022
With so much interest and investment in target protein degradation, a lot can happen in a year. Here are 9 conferences to get up-to-date on recent progress and the latest approaches. You’ll not...
-
ReadWays light scattering technologies help you if you’re in gene therapy
-
[New] Prometheus Panta with SLS
Learn more
Build effective AAV vectors for gene therapy with
high-quality stability profiling data -
Read
Four technologies to profile your AAVs
-
ReadNanoTemper Technologies and PharmAI launch Proto, a free AI tool to quickly determine optimal protein labeling strategy
MUNICH/DRESDEN, April 6, 2022—NanoTemper Technologies, in partnership with PharmAI, announced the launch of Proto, a free AI-based web application that reveals the best labeling strategy to help...
-
Read10 terms to help you more easily understand targeted protein degradation
Targeted Protein Degradation (TPD), a relatively new therapeutic approach, is making waves by targeting otherwise ‘undruggable’ proteins. PROTACs are the best-understood protein degraders, with...
-
ReadNanoTemper Technologies launches Spectral Shift, a breakthrough technology that changes the game for affinity-based screenings
NanoTemper Technologies, announced today the launch of Spectral Shift technology within their Dianthus instrument, built to handle the most challenging affinity-based screenings in drug discovery....
-
Have a question?
Contact Specialist -
Read
Finally tackle your most challenging affinity screenings with breakthrough Spectral Shift technology with Dianthus
-
2:30WatchDianthus: Tackle your most challenging affinity screenings with breakthrough Spectral Shift technology
-
ReadJourney of an mAb through IND and BLA filing
-
1:41WatchPrometheus Panta: The new gold standard for biologics characterization
Choosing the right stability characterization tool for your biologics research is a big commitment. You’re going to be screening and optimizing lots of candidates, and you’ll need data on thermal stab
-
ReadNanoTemper Technologies arms gene therapy scientists with Static Light Scattering to sharpen their tool kit for development of AAVs
SOUTH SAN FRANCISCO, Calif Feb 16 2022 — NanoTemper Technologies today announced the addition of Static Light Scattering (SLS) to their wildly successful Prometheus Panta, turning their instrument...
-
ReadA new spectral shift-based method to characterize molecular interactions
-
Read
Use stability profiling to build more effective gene therapy vectors with Prometheus Panta
-
Read
Use of self-interaction parameters derived from light scattering experiments for better developability assessment of biologic therapeutics
-
ReadHow do you get reproducible data from protein characterization experiments? Try following this DIN SPEC
Reproducibility is a key tenet of scientific research, but many pharma groups have projects that collaborate across different sites or that rely on materials prepared by other specialist...
-
21:48WatchHow to improve outcomes of your viral vectors for gene therapy with high-quality data from biophysical profiling methods
Optimizing your vectors for gene therapy is a daunting task. When developing and optimizing AAVs, concerns such as serotype, storage stability, expression method, and genetic fill level must be addres
-
25:08WatchOvercome bottlenecks in viral vector manufacturing
The success of your gene therapy vectors is dependent on optimal formulation conditions. Finding a buffer that provides better long-term stability for AAVs is a crucial step in the process of developi
-
Loading more...
